- Home
- CELU
CELU
Celularity Inc.
as 12-18-2024 3:33pm EST
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 49.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 240.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $7.97 | Next Earning Date: | 11-07-2024 |
| Revenue: | $48,200,000 | Revenue Growth: | 225.94% |
| Revenue Growth (this year): | -12.08% | Revenue Growth (next year): | 233.89% |
Latest Celularity Inc. News
CELU Breaking Stock News: Dive into CELU Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
GlobeNewswire
12 days ago
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
GlobeNewswire
21 days ago
Celularity Inc. Announces Receipt of Nasdaq Notification
GlobeNewswire
a month ago
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
GlobeNewswire
a month ago
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
GlobeNewswire
a month ago
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
GlobeNewswire
2 months ago
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
GlobeNewswire
2 months ago
Celularity Provides Corporate Update
Compare CELU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELU Celularity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.